Ian Maze, PhD, Named 2022 Recipient of Jacob P. Waletzky Award by Society for Neuroscience
The Society for Neuroscience (SfN) has named Ian Maze, PhD, as the 2022 recipient of the Jacob P. Waletzky Award. The award, supported by the Waletzky Award Prize Fund and the Waletzky family, is granted to a young scientist whose independent research has led to significant conceptual and empirical contributions to the understanding of drug addiction.
Dr. Maze is a Professor of Neuroscience and Pharmacological Sciences, Director of the Center for Neural Epigenome Engineering, and Principal Investigator of the Laboratory for Mechanistic Neuroepigenetics and Disease at the Icahn School of Medicine at Mount Sinai.
Dr. Maze is a chromatin biologist and neuroscientist investigating the complex interplay between chromatin regulatory mechanisms and neural plasticity in the mammalian central nervous system. His multidisciplinary and integrative research involves the use of biochemical, biophysical, physiological, and behavioral analyses to explore the molecular underpinnings of neurodevelopmental and adult cognitive, psychiatric, and substance use disorders.
“Dr. Maze is an outstanding scientist who is not afraid to challenge conventional scientific theories in pursuit of novel pathways towards our understanding and treatment of drug addiction,” said Eric J. Nestler, MD, PhD, Dean for Academic Affairs, Nash Family Professor of Neuroscience, and Director of The Friedman Brain Institute at Icahn Mount Sinai, Chief Scientific Officer of the Mount Sinai Health System, and past president of the Society for Neuroscience. “Ian has already made significant contributions to The Friedman Brain Institute here at Mount Sinai and to the field of neuroscience, and he is just getting started. We are thrilled and profoundly grateful to SfN and the Waletzky family for their recognition of Dr. Maze’s early-career excellence and for the investment they’ve made to advance his exceptional, innovative research.”
Dr. Maze was one of the early pioneers of the addiction neuroepigenetics field, and his lab’s latest research has upended the long-held scientific dogma that the neurotransmitters dopamine and serotonin (which also contribute to drug addiction and depression) serve only as messengers within the central nervous system, allowing brain cells to communicate with each other. In addition to their roles as messengers, he has found, the chemicals are able to change the fundamental biology and behavior of brain cells by directly attaching to proteins.
Dr. Maze and his lab team extract proteins from brain cells in animal models and postmortem tissues and examine how they are chemically modified or changed. His team has identified thousands of proteins modified by dopamine and serotonin in the brain using mass spectrometry and other approaches, and they continue to search for new protein modifications and how they affect brain cells. Another avenue of research is exploring specific categories of drugs of abuse that may also function by directly or indirectly modifying proteins in our cells. In recent studies from 2020 and 2022 on cocaine and opioid dependence, published in Science and Neuropsychopharmacology respectively, Dr. Maze and team showed that by manipulating these types of marks in the brain’s reward circuitry in animal models they could reduce the tendency to relapse into addiction.
“It is truly a tremendous honor to receive this award and be able to follow in the footsteps of so many incredible researchers who have contributed so significantly to the addiction field. I would like to thank the Waletzky family, as well as the SfN, for their generous support of our work,” Dr. Maze said.
Among other accolades, Dr. Maze was named a Howard Hughes Medical Institute Investigator in 2021. He is a recipient of the 2022 McKnight Brain Disorder Award, the 2019 Dr. Harold and Golden Laport Basic Research Award, the 2019 Presidential Early Career Award for Scientists and Engineers, the 2016 Sloan Foundation Fellowship in Neuroscience, and the 2015 MQ: Transforming Mental Health Research Fellowship Award.
Dr. Maze received the award on Saturday, November 12 at the beginning of the Presidential Special Lecture during SfN Neuroscience 2022in San Diego.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in several pediatric specialties.